(Reuters) – Europe’s medicines regulator said on Thursday there was insufficient evidence to support use of inhaled corticosteroids to treat patients with COVID-19, but said there was enough data at present to continue usage of dexamethasone.
The European Medicines Agency said although its COVID-19 taskforce had not found any safety risks so far for the corticosteroids, it could not exclude the possibility of harm in patients who have normal oxygen levels.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Krishna Chandra Eluri)
